@article{eaa1f726c61e40138bb17919a5550b0c,
title = "Patient-reported outcomes in the Translational Breast Cancer Research Consortium",
abstract = "Members of the Translational Breast Cancer Research Consortium conducted an expert-driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer-reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient-reported outcomes in relevant patients.",
keywords = "breast cancer consortium, breast cancer treatment, clinical trials, patient-reported outcomes, translational clinical judgements",
author = "Bowen, {Deborah J.} and Shinn, {Eileen H.} and Sophie Gregrowski and Gretchen Kimmick and Dominici, {Laura S.} and Frank, {Elizabeth S.} and Smith, {Karen Lisa} and Gabrielle Rocque and Ruddy, {Kathryn J.} and Teri Pollastro and Michelle Melisko and Ballinger, {Tarah J.} and Fayanju, {Oluwadamilola M.} and Wolff, {Antonio C.}",
note = "Funding Information: Funded by The Breast Cancer Research Foundation and Susan G. Komen. Oluwadamilola M. Fayanju is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under award number 1KL2TR002554. Oluwadamilola M. Fayanju and Gretchen Kimmick also are supported by the Duke Cancer Institute through NIH grant P30CA014236. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or any of its components. Funding Information: Funded by The Breast Cancer Research Foundation and Susan G. Komen. Oluwadamilola M. Fayanju is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under award number 1KL2TR002554. Oluwadamilola M. Fayanju and Gretchen Kimmick also are supported by the Duke Cancer Institute through NIH grant P30CA014236. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or any of its components. Gretchen Kimmick has acted as a paid member of the Scientific Advisory Board for Boehringer Ingelheim, Genomic Health, and Agendia; has acted as a paid member of the Scientific Advisory Board and Speakers Bureau for Eisai; has received research funding from Puma, Bionovo, and Roche; and has received royalties from UpToDate for work performed outside of the current study. Karen Lisa Smith has received research support from Pfizer for work performed outside of the current study. Her spouse has stock in ABT Laboratories and Abbvie. Kathryn J. Ruddy inherited stock from Merck and Pfizer and sold both stock options in February 2018. Michelle Melisko reports that her spouse owns stock in Merrimack Pharmaceuticals and receives honorarium from Pfizer and Genentech and she herself has received honoraria from Agendia and research funding to UC Regents from Novartis, Puma, KCRN Research, Astra Zeneca, Nektar, and Lilly for work performed outside of the current study. Tarah J. Ballinger has received personal fees from Novartis for work performed outside of the current study. Oluwadamilola M. Fayanju has received grants from the National Institutes of Health (grants 1KL2TR002554 and P30CA014236) for work performed as part of the current study. The other authors made no disclosures. Funding Information: Gretchen Kimmick has acted as a paid member of the Scientific Advisory Board for Boehringer Ingelheim, Genomic Health, and Agendia; has acted as a paid member of the Scientific Advisory Board and Speakers Bureau for Eisai; has received research funding from Puma, Bionovo, and Roche; and has received royalties from UpToDate for work performed outside of the current study. Karen Lisa Smith has received research support from Pfizer for work performed outside of the current study. Her spouse has stock in ABT Laboratories and Abbvie. Kathryn J. Ruddy inherited stock from Merck and Pfizer and sold both stock options in February 2018. Michelle Melisko reports that her spouse owns stock in Merrimack Pharmaceuticals and receives honorarium from Pfizer and Genentech and she herself has received honoraria from Agendia and research funding to UC Regents from Novartis, Puma, KCRN Research, Astra Zeneca, Nektar, and Lilly for work performed outside of the current study. Tarah J. Ballinger has received personal fees from Novartis for work performed outside of the current study. Oluwadamilola M. Fayanju has received grants from the National Institutes of Health (grants 1KL2TR002554 and P30CA014236) for work performed as part of the current study. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2019 American Cancer Society",
year = "2020",
month = mar,
day = "1",
doi = "10.1002/cncr.32615",
language = "English (US)",
volume = "126",
pages = "922--930",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",
}